Sanhome is a pharmaceutical company founded in 1996 with a mission to serve the society and improve health of patients around the world. Headquartered in Nanjing with over 1000 employees, Sanhome has established R&D center, GMP manufacturing lines for over 10 dosage forms, automatic distribution centers, a variety of drug products and a sales and marketing and sales network throughout China. At Sanhome, one founding principle is driving growth through innovation. Its R&D center has independently developed over 50 Chinese traditional medicine and western medicine products and generated over 100 patents. Among those, L-ornidazole, a new chemical entity with international patents, has been approved in China as a 1st class new drug in 2009. Registration of L-ornidazole is currently underway for US and EU markets. A great number of its products including onidazole injection and azithromycin injection, have been certified as the "New and High-tech Product" and "Name Brand Product" in China. Sanhome is listed among the "New and High-tech Enterprises" by Science and Technology Department of Jiangsu Province and is certified as one of the national "Key New and High-tech Enterprises" by the Ministry of Science and Technology of China. Under the strong support of the governments, the employees and the society, Sanhome follows a developing strategy of "high tech, high speed and high efficiency". Endeavored to discover new medicines, Sanhome is trying every means to contribute to the health cause of human being around the globe.